Navigation Links
After Heart Attack, Certain Painkillers May Raise Risk for Recurrence
Date:5/9/2011

By Maureen Salamon
HealthDay Reporter

MONDAY, May 9 (HealthDay News) -- People with a history of heart attack are at increased risk of suffering another attack or dying after even a week of taking certain types of prescription and over-the-counter painkillers, including Advil, Motrin or Voltarin, a large new study suggests.

Danish researchers analyzed nationwide records of almost 84,000 heart attack survivors and found that those who used certain non-steroidal anti-inflammatory drugs (NSAID) for one week faced a 45 percent heightened risk of another heart attack. Three months' use raised the risk to 55 percent.

The results reinforce a 2007 American Heart Association statement advising doctors about the risk of NSAID use among heart patients and recommending the drugs be used only in the lowest dose and for the shortest duration necessary.

"The present results indicate there is no apparent safe therapeutic window for NSAIDs in patients with prior [heart attack], and challenge the current recommendations of low-dose and short-term use of NSAIDs as being safe," said study author Dr. Anne-Marie Schjerning Olsen, a research fellow at Copenhagen University in Denmark.

The study is published online May 9 in the journal Circulation.

The most common NSAIDs prescribed to study participants were ibuprofen (Advil, Motrin) and diclofenac (Cataflam, Voltaren). Diclofenac carried the highest cardiovascular risk, even greater than rofecoxib (Vioxx), an NSAID banned in the United States in 2004 because of a higher rate of heart attacks and strokes among those taking it.

The U.S. Food and Drug Administration recently issued a warning that diclofenac should not be used by patients recovering from heart surgery.

One popular NSAID, naproxen (Aleve), was not associated with a greater risk of death or recurrent heart attack in the study, although it has been linked to gastrointestinal bleeding.

"W
'/>"/>

Copyright©2010 ScoutNews,LLC.
All rights reserved  

Page: 1 2 3

Related medicine news :

1. Risk for Problem Drinking May Rise After Gastric Bypass
2. Large study finds CT scans are frequently unnecessary after head injury in children
3. Most Leukemia Patients Recover From Chemo Brain After Transplant: Study
4. Most patients recover from chemo-brain by 5 years after stem cell transplant
5. Flu Vaccine Appears Safe After Kidney Transplant
6. Womens Kidneys May Be at Higher Risk After Heart Test
7. After Treatment for Precancerous Cervical Lesions, Risk Drops to Normal for Some
8. Deaths from drug overdose decline 35 percent after the opening of supervised injection site
9. How can we measure infants pain after an operation?
10. Depression Common After Brain Injury
11. Shorter Hospital Stays, More Readmissions After Hip Replacements
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
After Heart Attack, Certain Painkillers May Raise Risk for Recurrence
(Date:5/30/2015)... (PRWEB) May 30, 2015 San ... that she is offering a free analysis and consultation ... offer coincides with Disability Awareness Month, which was created ... members across the United States such as Polk recognize ... raise awareness about the possibility of disability, as well ...
(Date:5/30/2015)... Miami, FL (PRWEB) May 30, 2015 ... (NLHEP) partners with Pulmonary Horizons to offer one ... to effectively identify and discuss successful practices to diagnose, ... of Attending the Pulmonary Horizons Conference is ... that can address the Overall Needs of Patients with ...
(Date:5/30/2015)... Las Vegas, Nevada (PRWEB) May 30, 2015 ... effective treatment of acne scars, large pores, deep wrinkles, ... by a licensed medical professional, such as Dr. F. ... conducted some of the clinical trials in Las Vegas. ... and SmartScan technology into a system that delivers proven ...
(Date:5/29/2015)... Montclair, NJ (PRWEB) May 30, 2015 ... and ever changing local and federal regulations, we ... needs of their patients who are suffering from ... regulations,” says Srinivas Nalamachu, MD, professor of rehabilitation ... Research Institute in Overland Park, Kansas. , A ...
(Date:5/29/2015)... May 29, 2015 What does community ... Denver Foundation, community comes together to plant gardens, to ... neighborhoods and awareness of critical issues. Community invites everyone ... and beyond. , "What Community Does" was commissioned by ... in Colorado, and released during the foundation’s Annual Celebration ...
Breaking Medicine News(10 mins):Health News:San Luis Obispo Insurance Agent Susan Polk Offering Complementary Insurance Analysis In Honor Of Disability Awareness Month 2Health News:Pulmonary Horizons 2nd Annual COPD Conference Miami Hilton Downtown, July 17-19, 2015 Patient Centered Cross-Continuum Education to Improve the Care of Patients with COPD 2Health News:Pulmonary Horizons 2nd Annual COPD Conference Miami Hilton Downtown, July 17-19, 2015 Patient Centered Cross-Continuum Education to Improve the Care of Patients with COPD 3Health News:Announcing Ground-Breaking Technology for Anti-Aging, FDA Approved, Venus Viva. 2Health News:Announcing Ground-Breaking Technology for Anti-Aging, FDA Approved, Venus Viva. 3Health News:PAINWeekEnd Kansas City: Pain Management CME for the Main Street Practitioner 2Health News:What Community Does: A New Video from The Denver Foundation 2
... Pharmaceuticals, Inc. (OTC Bulletin Board: TDLP) a specialty pharmaceutical ... that they anticipate reporting top-line results from their current ... of 2009. , , The Phase ... trial to evaluate the efficacy and safety of Ketotransdel, ...
... High Resolution Monitoring of Drug Efficacy and Safety ... Based on its recent analysis in the ... & Sullivan recognizes Singulex, Inc. with the 2009 ... Innovation for pioneering the Erenna Immunoassay System. This ...
... NTY ) ( www.NBTY.com ), a leading global manufacturer and marketer of nutritional supplements, today announced the ... unaudited net sales results for May 2009 by segment are as follows: , , , ... NET SALES, ... (Preliminary and Unaudited), ...
... -- As the slumping economy continues to ... streamlining costs and creating additional efficiencies while continuing to ... those in need for charity care or self-pay discounts. ... landscape, TransUnion announced today new enhancements to its patented ...
... ... seniors nationwide. , ... (Vocus) June 15, 2009 -- VaxAmerica, a program of FFF Enterprises, Inc., ... into a partnership with Emeritus Senior Living. The alliance will encourage the 26,500 seniors ...
... ... have developed the strongest and most effective libido/intimacy enhancement therapy called VaietTM 110/L-Arginine for ... ... to announce the release of their exclusive Viagra/Arginine Intimacy Enhancement Therapy or VAIET (named ...
Cached Medicine News:Health News:Transdel Pharmaceuticals Provides Update on Timing of Results for Phase 3 Study 2Health News:Transdel Pharmaceuticals Provides Update on Timing of Results for Phase 3 Study 3Health News:Frost & Sullivan Recognizes Singulex for Erenna(R) Immunoassay System 2Health News:Frost & Sullivan Recognizes Singulex for Erenna(R) Immunoassay System 3Health News:Frost & Sullivan Recognizes Singulex for Erenna(R) Immunoassay System 4Health News:NBTY Announces Preliminary Unaudited Net Sales Results for May 2009 2Health News:NBTY Announces Preliminary Unaudited Net Sales Results for May 2009 3Health News:NBTY Announces Preliminary Unaudited Net Sales Results for May 2009 4Health News:TransUnion Revenue Manager(SM) Meets Healthcare Challenges Brought On By Today's Economy with New Features 2Health News:TransUnion Revenue Manager(SM) Meets Healthcare Challenges Brought On By Today's Economy with New Features 3Health News:VaxAmerica Enters Partnership with Emeritus Senior Living 2Health News:VaxAmerica Enters Partnership with Emeritus Senior Living 3Health News:After 10 Years A Stronger and More Enhanced Form of Viagra Now Available 2Health News:After 10 Years A Stronger and More Enhanced Form of Viagra Now Available 3Health News:After 10 Years A Stronger and More Enhanced Form of Viagra Now Available 4
(Date:5/29/2015)... 2015 Research and Markets ... the "Surgical/Operating Microscopes Market by Application & ... report to their offering.      (Logo: ... is poised to reach $806.6 million by 2020 ... of 12.3% from 2015 to 2020. , ,Major ...
(Date:5/29/2015)... British Columbia and MENLO ... -- DelMar Pharmaceuticals, Inc. (OTCQX: DMPI) ... on developing and commercializing proven cancer therapies in ... at the American Association of Cancer Research ... on the potential for its lead product candidate ...
(Date:5/29/2015)... 2015 Amgen (NASDAQ: AMGN ) ... 3, global, randomized, placebo-controlled trials evaluating AMG 416, ... hyperparathyroidism (SHPT) in patients with chronic kidney disease ... endpoint, demonstrating that a greater proportion of patients ... than 30 percent reduction in parathyroid hormone (PTH) ...
Breaking Medicine Technology:Surgical/Operating Microscopes Market by Application & End User - Global Forecast to 2020 for the $806 Million Industry 2DelMar Pharmaceuticals Presents Additional Data on the Potential of VAL-083 in the Treatment of Temozolomide-Resistant Glioblastoma Multiforme 2DelMar Pharmaceuticals Presents Additional Data on the Potential of VAL-083 in the Treatment of Temozolomide-Resistant Glioblastoma Multiforme 3DelMar Pharmaceuticals Presents Additional Data on the Potential of VAL-083 in the Treatment of Temozolomide-Resistant Glioblastoma Multiforme 4DelMar Pharmaceuticals Presents Additional Data on the Potential of VAL-083 in the Treatment of Temozolomide-Resistant Glioblastoma Multiforme 5Amgen Presents Pooled Phase 3 AMG 416 Data For The Treatment Of Secondary Hyperparathyroidism In Patients With Chronic Kidney Disease 2Amgen Presents Pooled Phase 3 AMG 416 Data For The Treatment Of Secondary Hyperparathyroidism In Patients With Chronic Kidney Disease 3Amgen Presents Pooled Phase 3 AMG 416 Data For The Treatment Of Secondary Hyperparathyroidism In Patients With Chronic Kidney Disease 4Amgen Presents Pooled Phase 3 AMG 416 Data For The Treatment Of Secondary Hyperparathyroidism In Patients With Chronic Kidney Disease 5Amgen Presents Pooled Phase 3 AMG 416 Data For The Treatment Of Secondary Hyperparathyroidism In Patients With Chronic Kidney Disease 6Amgen Presents Pooled Phase 3 AMG 416 Data For The Treatment Of Secondary Hyperparathyroidism In Patients With Chronic Kidney Disease 7
Shielding's new Surgical Drop Away / Flex Back Apron offers top of the shoulder velcro flaps for an adjustable fit. Features elastic back panels for added comfort and support. For quick removal apron...
Shielding's Standard Coat Apron with open back allows for freedom of movement, maximum flexibility and increased comfort....
This set includes 2 small, 1 medium, 1 large gonad shields and a belt. The shields and belt is an interchangeable system attached by velcro....
Lap pad used to protect pelvic regions...
Medicine Products: